Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcos Bazarra-Barreiros has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Pablo Hervella

    Neuroimaging and Biotechnology Laboratory (NOBEL), Health Research Institute of Santiago de Compostela, Spain

    7 shared publications
  • Ramón Iglesias-Rey

    Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, A Coruña, Spain

    7 shared publications
  • Maria Luz Alonso-Alonso

    Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, A Coruña, Spain

    6 shared publications
  • Ana Sampedro-Viana

    Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain

    5 shared publications
  • Francisco Campos

    Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain

    5 shared publications
  • José Castillo

    Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain

    5 shared publications

Latest Publications

  • Open Access

    2D U‐Net Framework for Multiclass Automated Segmentation of Healthy Structures, Ischemic Stroke, and Glioblastoma in the Rat Brain

    by Sara Ortega‐Espina, Sabela Fernández‐Rodicio, María Luz Alonso‐Alonso, Pelayo García‐Acevedo, Ana Sampedro‐Viana, Marcos Bazarra‐Barreiros, María Teresa Abengoza‐Bello, Antonio J. Mosqueira, Jacobo Porto‐Álvarez, Javier Martínez Fernández, et al.

    Rodents are essential for preclinical brain disease research, including stroke, tumors, and neurodegenerative disorders. Magnetic resonance imaging (MRI) enables longitudinal brain tissue visualization, but accurate segmentation is crucial for meaningful analysis. This study introduces a multitask 2D U‐Net, a convolutional neural network designed for automated segmentation and quantification of brain regions, ischemic stroke lesions, and tumors in rats using T 2 ‐weighted imaging (T 2 ‐wi) and T 2 ‐relaxation maps. The model was evaluated on the following three MRI datasets: (i) segmentation of multiple brain regions in healthy rats, (ii) ischemic stroke lesions using T 2 ‐relaxation maps, and (iii) glioblastoma tumors using T 2 ‐wi. Performance was assessed using the Dice coefficient (DC), Hausdorff distance (HD), sensitivity (SEN), and volume ratio (VR), comparing network outputs against semiautomatic ground truths and existing models. A total of 1949 images from 111 rats were analyzed, expanded to 5847 through data augmentation. After correcting an animal‐level train/test partitioning that prevented data leakage between subjects, the model achieved robust accuracy across all tasks (DC = 0.80–0.96, HD = 0.83–2.16 mm, SEN = 0.75–0.96, VR = 0.89–1.10), showing a strong correlation () with manual annotations. This framework improves segmentation accuracy, robustness, and applicability across different MRI settings and conditions, addressing issues like interrater variability and time inefficiency when analyzing rodent brain MRI data. Datasets are publicly available at https://github.com/NOBEL‐MRI/Rat‐Datasets .

  • Open Access

    Asymptotic r 2 Enhancement in Formulation‐Optimized Lipid‐Iron Oxide Nanoparticles for Assessing Glioblastoma Heterogeneity at Ultrahigh‐Field MRI

    by Marcos Bazarra‐Barreiros, María Teresa Abengoza‐Bello, Sabela Fernández‐Rodicio, Sara Ortega‐Espina, Lucía García‐Astray, José Castillo, Ramón Iglesias‐Rey, Pelayo García‐Acevedo, Pablo Hervella

    Glioblastoma (GBM) remains a major challenge for nanomedicine because heterogeneous tumor vascularization and the blood–brain barrier cause variable nanoparticle accumulation. Here, we developed lipid‐coated superparamagnetic iron oxide nanoparticles (LSPIONs) as MRI‐visible lipid nanocarriers and established a formulation‐based strategy to control their transverse relaxivity (r 2 ). Hydrophobic iron oxide nanoparticles (IO@OA) were incorporated into a DSPC/cholesterol/DSPE‐PEG lipid matrix via solvent displacement, enabling systematic control of nanoparticle size, polydispersity, and SPION loading, with r 2 values ranging from 13 to 418 m m − 1 s − 1 at 9.4 T. The relaxivity showed an asymptotic dependence on nanoparticle size (54–184 nm) and estimated iron oxide nanoparticles per lipid nanoparticle (237–9284), revealing a saturation regime. The optimized formulation, obtained at a lipid‐to‐IO@OA molar ratio of 8.3 (D H = 98 nm, PDI = 0.14), was evaluated in a syngeneic GL261‐GFP GBM mouse model. Intravenous administration induced an initial reduction in GBM‐associated MRI signal, with detectable tumor retention at 24 h in tumors assessed at 1 and 2 weeks after inoculation. Intravital multiphoton microscopy further confirmed LSPION extravasation and GBM accumulation. These results establish formulation control of r 2 as a key design strategy for MRI‐visible lipid nanocarriers and provide an experimental framework for lipid‐based nanoprobes for GBM imaging.

  • Open Access

    Molecular and Neuroimaging Profile Associated with the Recurrence of Different Types of Strokes: Contribution from Real-World Data

    by Crhistian-Mario Oblitas, Ana Sampedro-Viana, Sabela Fernández-Rodicio, Manuel Rodríguez-Yáñez, Iria López-Dequidt, Arturo Gonzalez-Quintela, Antonio J. Mosqueira, Jacobo Porto-Álvarez, Javier Martínez Fernández, Inmaculada González-Simón, et al.

    Objective: This study aimed to investigate potential specific molecular and neuroimaging biomarkers for stroke subtype recurrence to improve secondary stroke prevention. Methods: A retrospective analysis was conducted on a prospective stroke biobank. The main endpoint was to evaluate the association between different biomarkers and the recurrence of stroke subtypes. Serum levels of interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-a) were analyzed as inflammation biomarkers; N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) and microalbuminuria were used as atrial/endothelial dysfunction biomarkers, while leukoaraiosis (LA) and soluble TNF-like inducers of apoptosis (sTWEAK) were used as biomarkers for blood–brain barrier dysfunction. Demographic and clinical variables were also included. Results: A total of 5038 stroke patients were included, with a mean follow-up of 4.9 years (±3.3). Stroke recurrences were observed in 18.4% of patients (927 individuals). The main results found were as follows: LA was independently associated with lacunar stroke recurrence (adjusted OR 9.50; 95% CI: 3.12–28.93). NT-pro-BNP levels higher than >1000 pg/mL were independently associated with cardioembolic stroke recurrence (adjusted OR 1.80; 95% CI: 1.23–2.61). Persistently elevated TNF-a levels (>24 pg/mL) after stroke recurrence showed an adjusted OR of 21.26 (95% CI: 12.42–37.59) for atherothrombotic subtype, whereas persistently high sTWEAK levels (>7000 pg/mL) after a second hemorrhagic stroke showed an adjusted OR of 4.81 (95% CI: 2.86–8.07) for hemorrhagic subtype. Conclusions: The presence of LA and high levels of NT-pro-BNP, TNF-a, and sTWEAK were associated with an increased risk for lacunar, cardioembolic, atherothrombotic, and hemorrhagic stroke recurrences, respectively.


  • Open Access

    Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke

    by Pablo Hervella, Ana Sampedro-Viana, Sabela Fernández-Rodicio, Manuel Rodríguez-Yáñez, Iria López-Dequidt, José M. Pumar, Antonio J. Mosqueira, Marcos Bazarra-Barreiros, María Teresa Abengoza-Bello, Sara Ortega-Espina, et al.

    Glutamate grabbers, such as glutamate oxaloacetate transaminase (GOT), have been proposed to prevent excitotoxicity secondary to high glutamate levels in stroke patients. However, the efficacy of blood glutamate grabbing by GOT could be dependent on the extent and severity of the disruption of the blood–brain barrier (BBB). Our purpose was to analyze the relationship between GOT and glutamate concentration with the patient’s functional status differentially according to BBB serum markers (soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and leukoaraiosis based on neuroimaging). This retrospective observational study includes 906 ischemic stroke patients. We studied the presence of leukoaraiosis and the serum levels of glutamate, GOT, and sTWEAK in blood samples. Functional outcome was assessed using the modified Rankin Scale (mRS) at 3 months. A significant negative correlation between GOT and glutamate levels at admission was shown in those patients with sTWEAK levels > 2900 pg/mL (Pearson’s correlation coefficient: −0.249; p < 0.0001). This correlation was also observed in patients with and without leukoaraiosis (Pearson’s correlation coefficients: −0.299; p < 0.001 vs. −0.116; p = 0.024). The logistic regression model confirmed the association of higher levels of GOT with lower odds of poor outcome at 3 months when sTWEAK levels were >2900 pg/mL (OR: 0.41; CI 95%: 0.28–0.68; p < 0.0001) or with leukoaraiosis (OR: 0.75; CI 95%: 0.69–0.82; p < 0.0001). GOT levels are associated with glutamate levels and functional outcomes at 3 months, but only in those patients with leukoaraiosis and elevated sTWEAK levels. Consequently, therapies targeting glutamate grabbing might be more effective in patients with BBB dysfunction.


  • Open Access

    Systemic biomarker associated with poor outcome after futile reperfusion

    by Pablo Hervella, Ana Sampedro‐Viana, Manuel Rodríguez‐Yáñez, Iria López‐Dequidt, José M. Pumar, Antonio J. Mosqueira, Sabela Fernández‐Rodicio, Marcos Bazarra‐Barreiros, Joaquín Serena, Yolanda Silva‐Blas, et al.

    Background: Successful recanalization does not lead to complete tissue reperfusion in a considerable percentage of ischemic stroke patients. This study aimed to identify biomarkers associated with futile recanalization. Leukoaraiosis predicts poor outcomes of this phenomenon. Soluble tumour necrosis factor‐like weak inducer of apoptosis (sTWEAK), which is associated with leukoaraiosis degrees, could be a potential biomarker.Methods: This study includes two cohorts of ischemic stroke patients in a multicentre retrospective observational study. Effective reperfusion, defined as a reduction of ≥8 points in the National Institutes of Health Stroke Scale (NIHSS) within the first 24 h, was used as a clinical marker of effective reperfusion.Results: In the first cohort study, female sex, age, and high NIHSS at admission (44.7% vs. 81.1%, 71.3 ± 13.7 vs. 81.1 ± 6.7; 16 [13, 21] vs. 23 [17, 28] respectively; p < .0001) were confirmed as predictors of futile recanalization. ROC curve analysis showed that leukocyte levels (sensitivity of 99%, specificity of 55%) and sTWEAK level (sensitivity of 92%, specificity of 88%) can discriminate between poor and good outcomes. Both biomarkers simultaneously are higher associated with outcome after effective reperfusion (OR: 2.17; CI 95% 1.63–4.19; p < .0001) than individually (leukocytes OR: 1.38; CI 95% 1.00–1.64, p = .042; sTWEAK OR: 1.00; C I95% 1.00–1.01, p = .019). These results were validated using a second cohort, where leukocytes and sTWEAK showed a sensitivity of 100% and specificity of 66.7% and 75% respectively.Conclusions: Leukocyte and sTWEAK could be biomarkers of reperfusion failure and subsequent poor outcomes. Further studies will be necessary to explore its role in reperfusion processes.


  • Open Access

    Influence of Temperature Chronobiology on Stroke Outcome

    by Maria Luz Alonso-Alonso, Ana Sampedro-Viana, Manuel Rodríguez-Yáñez, Iria López-Dequidt, José M. Pumar, Antonio J. Mosqueira, Sabela Fernández-Rodicio, Marcos Bazarra-Barreiros, Tomás Sobrino, Francisco Campos, et al.

    The circadian system regulates numerous physiological variables, including body temperature. Additionally, a circadian patter has been described in stroke onset. Considering this, we hypothesised that the chronobiology of temperature may have an impact on stroke onset and functional outcomes. We also studied the variation of blood biomarkers according to stroke onset time. This is a retrospective observational study. Of the patients included, 2763 had a stroke between midnight and 8:00 h; 1571 between 8:00–14:00 h; and 655 between 14:00 h and midnight. Axillary temperature was measured at admission. At this time, blood samples were collected for biomarker analysis (TNF-α, IL-1β, IL-6, IL-10, and glutamate). Temperature was higher in patients admitted from 8:00 h to midnight (p < 0.0001). However, the percentage of poor outcome at 3 months was highest in patients from midnight to 8:00 h (57.7%, p < 0.001). The association between temperature and mortality was highest during night time (OR: 2.79; CI 95%: 2.36–3.28; p < 0.001). These patients exhibited high glutamate (220.2 ± 140.2 µM), IL-6 (32.8 ± 14.3 pg/mL) and low IL-10 (9.7 ± 14.3 pg/mL) levels. Therefore, temperature chronobiology could have a significant impact on stroke onset and functional outcome. Superficial body hyperthermia during sleep seems to be more dangerous than during wakefulness. Further studies will be necessary to confirm our data.


  • Open Access

    Need for a Paradigm Shift in the Treatment of Ischemic Stroke: The Blood-Brain Barrier

    by Maria Luz Alonso-Alonso, Ana Sampedro-Viana, Sabela Fernández-Rodicio, Marcos Bazarra-Barreiros, Alberto Ouro, Tomás Sobrino, Francisco Campos, José Castillo, Pablo Hervella, Ramón Iglesias-Rey

    Blood-brain barrier (BBB) integrity is essential to maintaining brain health. Aging-related alterations could lead to chronic progressive leakiness of the BBB, which is directly correlated with cerebrovascular diseases. Indeed, the BBB breakdown during acute ischemic stroke is critical. It remains unclear, however, whether BBB dysfunction is one of the first events that leads to brain disease or a down-stream consequence. This review will focus on the BBB dysfunction associated with cerebrovascular disease. An added difficulty is its association with the deleterious or reparative effect, which depends on the stroke phase. We will first outline the BBB structure and function. Then, we will focus on the spatiotemporal chronic, slow, and progressive BBB alteration related to ischemic stroke. Finally, we will propose a new perspective on preventive therapeutic strategies associated with brain aging based on targeting specific components of the BBB. Understanding BBB age-evolutions will be beneficial for new drug development and the identification of the best performance window times. This could have a direct impact on clinical translation and personalised medicine.